Prospective validation of a risk prediction model for severe sepsis in children with cancer and high-risk febrile neutropenia

Pediatric Infectious Disease Journal

Volumn 32, Issue 12, 2013, Pages 1318-1323

  Santolaya, Maria E ^a,b   Alvarez, Ana M ^b,c   Aviles, Carmen L ^a,b   Becker, Ana ^b,d   Venegas, Marcela ^a,b   O'Ryan, Miguel ^e   Salgado, Carmen ^b,f   Topelberg, Santiago ^b,g   Tordecilla, Juan ^b,g   Varas, Monica ^b,c   Villarroel, Milena ^a,b   Viviani, Tamara ^b,d   Zubieta, Marcela ^b,f   De La Maza, Veronica ^a   Vergara, Alejandra ^a   Farfan, Mauricio J ^a   Torres, Juan P ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b Infectious Diseases Committee   (Chile)

^c HOSPITAL SAN JUAN DE DIOS   (Chile)

^d HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^e Institute of Biomedical Sciences   (Chile)

^f Pediatra Reumatólogo Unidad Inmuno Reumatología Hospital Dr Exequiel González Cortés   (Chile)

^g HOSPITAL ROBERTO DEL RÍO   (Chile)

Author keywords

High risk febrile neutropenia; Sepsis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 8;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HIGH RISK FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MONOCYTOPENIA; MULTICENTER STUDY; NEUTROPENIA; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS; SCHOOL CHILD; SEPSIS; VALIDATION STUDY; BLOOD; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; MICROBIOLOGY; NEOPLASMS; PATHOLOGY; RISK; STATISTICAL MODEL;

ADOLESCENT; C-REACTIVE PROTEIN; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MODELS, STATISTICAL; NEOPLASMS; RISK; SEPSIS;

EID: 84891700152     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/01.inf.0000436128.49972.16     Document Type: Article

References (30)

1. Anaissie EJ, Vadhan-Raj S. Is it time to redefne the management of febrile neutropenia in cancer patients? Am J Med. 1995;98:221-223.
2. Klastersky J, Awada A, Paesmans M, et al. Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol. 2011;78:185-194.
3. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol. 1996;14:919-924.
4. Klaassen RJ, Goodman TR, Pham B, et al. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012-1019.
5. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.
6. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19:3415-3421.
7. Paganini H, Gómez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer. 2003;97:1775-1780.
8. Santolaya ME, Alvarez AM, Avilés CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol. 2004;22:3784-3789.
9. Oude Nijhuis C, Kamps WA, Daenen SM, et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol. 2005;23:7437-7444.
10. Kern W V, Heiss M, Steinbach G. Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis. 2001;32:832-835.
11. Basu SK, Fernandez ID, Fisher SG, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23:7958-7966.
12. Santolaya ME, Alvarez AM, Avilés CL, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J. 2007;26:794-798.
13. Santolaya ME, Alvarez AM, Avilés CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis. 2002;35:678-683.
14. Rondinelli PI, Ribeiro KDE C, De Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006;28:665-670.
15. Amman R, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multi-center SPOG 2003 FN study. J Clin Oncol 2010;28:2008-2014.
16. Santolaya ME, Alvarez AM, Aviles CL, et al. Predictors of severe sepsis not clinically apparent during the frst twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. Pediatr Infect Dis J. 2008;27:538-543.
17. Santolaya ME, Rabagliati R, Bidart T, et al.; Sociedad chilena de infectología; sociedad chilena de hematología. Consenso manejo racional del paciente con cáncer, neutropenia y febre. Rev Chil Infectol. 2005;22(suppl 2):S79-S113.
18. Paganini H, Santolaya ME. Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer. Consenso de la Sociedad Latinoamericana de Infectología Pediátrica. Rev Chil Infectol. 2010;28(suppl 1):S38.
19. Solís Y, Alvarez AM, Fuentes D, et al. Agentes causantes de bacteriemia en niños con cáncer y neutropenia febril de alto riesgo en seis hospitales de Santiago, Chile, período 2004-2009. Rev Chil Infectol. 2012;29:156-162.
20. Goldstein B, Giroir A, Randolph A; An international consensus conference on pediatric sepsis. International pediatric sepsis consensus conference: defnitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2-8.
21. Brilli RJ, Goldstein B. Pediatric sepsis defnitions: past, present, and future. Pediatr Crit Care Med. 2005;6(3 suppl):S6-S8.
22. Kern W V, Heiss M, Steinbach G. Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis. 2001;32:832-835.
23. Casagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics. 1978;34:483-486.
24. Lehrnbecher T, Phillips R, Alexander S, et al.; International pediatric fever and neutropenia guideline panel. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427-4438.
25. Cull LF, Nolan MB. Treating neutropenic fever in the emergency department: delays may be deadly! J Emerg Nurs. 2009;35:36-39.
26. Klastersky J. Why empirical therapy? J Antimicrob Chemother. 2009;63(suppl 1):i14-i15.
27. Lehrnbecher T, Venzon D, De HAAS M, et al. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 1999;29: 414-419.
28. Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med. 2011;12:165-173.
29. Wong HR, Cvijanovich N, Wheeler DS, et al. Interleukin-8 as a stratifcation tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med. 2008;178:276-282.
30. Urbonas V, Eidukaite A, Tamuliene I. The diagnostic value of interleu-kin-6 and interleukin-8 for early prediction of bacteremia and sepsis in children with febrile neutropenia and cancer. J Pediatr Hematol Oncol. 2012;34:122-127.